Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
2.25% $0.733
America/New_York / 25 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 116.55 mill |
EPS: | -0.260 |
P/E: | -2.82 |
Earnings Date: | May 10, 2024 |
SharesOutstanding: | 159.10 mill |
Avg Daily Volume: | 0.847 mill |
RATING 2024-04-25 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.82 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.48x |
Company: PE -2.82 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.172 (-76.54%) $-0.561 |
Date: 2024-04-26 |
Expected Trading Range (DAY) |
---|
$ 0.659 - 0.807 ( +/- 10.10%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Mazur Leonard L | Buy | 1 165 048 | Warrant to Purchase Common Stock |
2024-04-03 | Mazur Leonard L | Sell | 1 165 048 | Warrant to Purchase Common Stock |
2024-04-03 | Holubiak Myron Z | Buy | 129 450 | Warrant to Purchase Common Stock |
2024-04-03 | Holubiak Myron Z | Sell | 129 450 | Warrant to Purchase Common Stock |
2024-03-14 | Smith Robert Joseph | Buy | 75 000 | Stock Option (Right to Purchase Common Stock) |
INSIDER POWER |
---|
43.38 |
Last 96 transactions |
Buy: 27 334 255 | Sell: 1 367 765 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.733 (2.25% ) |
Volume | 0.582 mill |
Avg. Vol. | 0.847 mill |
% of Avg. Vol | 68.78 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.